For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of Vyndamax and Tafamidis meglumine represents a significant breakthrough . These innovative therapies protect the transthyretin protein, slowing its harmful build-up and lessening the imp